Aicuris to launch AiCubator to fight AMR
Antinfectives specialist AiCuris GmbH will launch the “AiCubator”, a new way to collaborate in anti-infectives and support novel approaches, at the 4th AMR Conference.
Under the new AiCuris accelerator, Aicuris will finance young researchers, who develop resistance breaking antiinfectives to advance their projects. Under the programme, AiCuris will offer them insights into from pre-clinical and clinical drug development, as well as know-how about the pharmaceutical business. The initiative to be launched at the 4th AMR Conference will provide long-term support for selected anti-infective projects in research or early pre-clinical stage.
Academic scientific groups or recently formed biotech start-ups with early stage anti-infectives projects are invited to apply to the AiCuris AiCubator. In this process, the main focus lies on Gram-negative resistance-breaking antibiotics, as well as targeted antiviral therapies for the treatment of herpes virus, adenovirus, hepatitis B cure and respiratory viruses. Submitted projects will be evaluated by AiCuris experts. Up to three projects per year will be awarded with AiCubator Resident Status. Over a period of up to three years the winning projects will mainly benefit from expert scientific support to grow their underlying ideas and approaches to an advanced level. The program was designed to help scientists and start-ups build their own business by providing financing and business development advice.
Applicants can submit their proposals until 31 September. The best projects will be announced in mid-December and will start on 1 January 2021.
AiCuris was founded in 2006 as a spin-off from Bayer and focuses on the discovery and development of drugs targeting infectious diseases.
+++ AiCuris at the 4th AMR Conference +++
Day 2, Tuesday, 25 August 2020, 09:30 – 11:00
Expert campus “How to accelerate AMR drug discovery & development”
Participant: Dr. Cuong Vuong
Day 2, Tuesday, 25 August 2020, 15:15 – 16:15
SME approach “How to develop strategic decision in a challenging and global AMR market”
Participant: Dr. Holger Zimmermann
Day 4, Thursday, 27 August 2020, 09:45 – 10:45
Start-up campus with pitches of innovators
Participant in the expert jury: Dr. Holger Zimmermann
Day 4, Thursday, 27 August 2020, 11:00 – 12:00
SME campus (Part I) “Focus on therapeutics”
Company presentation presented by: Dr. Holger Zimmermann
Day 4, Thursday, 27 August 2020, 16:30 – 17:30
Behind the scenes “Perspectives from Investors, Accelerators and Incubators”
Participant: Dr. Igor Orshanskiy